Home > Newsletters > Drug Industry Daily > Supreme Court Likely to Keep ‘Safe Harbor’ Broad, Boosting Generic and Biosimilar Makers: Expert
Drug Industry Daily
Aug. 30, 2012 | Vol. 11 No. 171
Supreme Court Likely to Keep ‘Safe Harbor’ Broad, Boosting Generic and Biosimilar Makers: Expert
The country’s highest court is likely to mull Hatch-Waxman’s safe-harbor provision now that the U.S. Court of Appeals for the Federal Circuit has issued contradictory rulings on when the law allows drugmakers to use others’ patents without fear of infringement.
SCOTUS “Pay-for-Delay” Decision Provides Roadmap for Case-by-Case CrackdownMomenta: SCOTUS Must Settle Uncertainty in Safe Harbor Landscape, Rule Against Amphastar Teva Prepping for Potential $2 Billion Loss in Protonix Patent FlapApotex Breaks From Pack, Offers Strong Critique of Pay-for-Delay to SCOTUS
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.